Loading company…
OverT Bio develops engineered T cell therapies for solid tumors using functional screening and synthetic genomics.
OverT Bio develops cellular therapies for solid tumors using its OverTarget and OverTune platforms to identify and engineer immune cells. Founded in 2022 and based in New York, the company is at the Seed stage. In May 2024, it raised USD 16 million co-led by ARTIS Ventures and Wing, with Fusion Fund, OMX Ventures, Alexandria Venture Investments, and other investors participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in